Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...